Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study

Alice Tison 1 Gilles Quéré 1 Laurent Misery 1 Elisa Funck-Brentano 2 François Danlos 3 Emilie Routier 4 Caroline Robert 4 Yohann Loriot 5 Olivier Lambotte 6 Bertille Bonniaud 7 Camille Scalbert 8 Sarah Maanaoui 8 Thierry Lesimple 9 Stéphanie Martinez 10 Marie Marcq 11 Christos Chouaid 12 Catherine Dubos 13 Florence Brunet-Possenti 14 Chloé Stavris 15 Laurent Chiche 15 Nathalie Beneton 16 Sandrine Mansard 17 Florian Guisier 18 Hélène Doubre 19 François Skowron 20 François Aubin 21 Ouidad Zehou 22 Christophe Roge 23 Mickaël Lambert 23 Anne Pham-Ledard 24 Marie Beylot-Barry 24 Rémi Veillon 24 Nora Kramkimel 25 Damien Giacchero 26 Julie De Quatrebarbes 27 Catherine Michel 28 Jean-Bernard Auliac 29 Gilles Gonzales 30 Chantal Decroisette 27 Gwenaelle Le Garff 31 Ioana Carpiuc 32 Hervé Vallerand 33 Emmanuel Nowak 1 Divi Cornec 34, 35 Marie Kostine 24
4 Oncologie dermatologique
Département de médecine oncologique [Gustave Roussy]
5 Oncologie génito-urinaire
Département de médecine oncologique [Gustave Roussy]
Abstract : Immune Checkpoint Inhibitors (ICI) for cancer therapy induce frequent Immune Related Adverse Effects (IRAE). Therefore, most patients with Preexisting Autoimmune Diseases (PAD) have been excluded from clinical trials. This study aims to evaluate the safety and efficacy of ICI in patients with PAD and cancer.
Document type :
Journal articles
Complete list of metadatas

https://hal.univ-brest.fr/hal-02267195
Contributor : Geneviève Michel <>
Submitted on : Monday, August 19, 2019 - 10:22:34 AM
Last modification on : Friday, November 8, 2019 - 10:51:22 AM

Identifiers

Citation

Alice Tison, Gilles Quéré, Laurent Misery, Elisa Funck-Brentano, François Danlos, et al.. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study. Arthritis & rheumatology, Wiley, 2019, ⟨10.1002/art.41068⟩. ⟨hal-02267195⟩

Share

Metrics

Record views

58